Search

Displaying results 1941 - 1950 of 4262 in total
  1. Drug

    Maralixibat

    go.drugbank.com/drugs/DB16226
    ApprovedInvestigational

    [L44396] On July 21, 2023, maralixibat was also approved by Health Canada.[L47541]

  2. Drug

    Darolutamide

    go.drugbank.com/drugs/DB12941
    ApprovedInvestigational

    [A189054,A189063] Darolutamide was developed by Bayer HealthCare Pharmaceuticals Inc. and approved by the FDA on July 30th, 2019.[L10887]

  3. Drug

    Drotaverine

    go.drugbank.com/drugs/DB06751
    ApprovedWithdrawn

    Drotaverine is an antispasmodic drug that works by inhibiting phosphodiesterase-4 (PDE4). … [A231619] Drotaverine is not approved by the FDA, European Medicines Agency, or Health Canada. It is approved for use in Thailand as oral tablets or intramuscular injections.[L22689]

  4. Drug

    Icaridin

    go.drugbank.com/drugs/DB14074
    Investigational

    Icaridin has been commonly used as a topically-applied insect repellent in various countries but was officially licensed for use in the United States in 2001 and Canada in 2012 [L4595]. … Icaridin was synthesized by Bayer in the 1980s based on molecular modeling [L4595].

  5. Drug

    Hexaminolevulinate

    go.drugbank.com/drugs/DB06261
    ApprovedInvestigational

    Hexaminolevulinate is manufactured under the brand Cysview® by Photocure ASA. In Europe, Hexaminolevulinate is marketed under the brand Hexvix®.

  6. Drug

    Nipocalimab

    go.drugbank.com/drugs/DB16257
    ApprovedInvestigational

    [L64042] It is administered by intravenous infusion.[L64042] Nipocalimab-aahu was first approved by the FDA in April 2025 for generalized myasthenia gravis.

  7. Drug

    Metrizoic acid

    go.drugbank.com/drugs/DB09346
    Approved

    In general, the drug was well tolerated by patients during cardiac examinations [A32091]. … Its approval has been discontinued by the FDA. One study in 1976 demonstrated that metrizoic acid, when used for cardiac angiography, was well tolerated.

  8. Drug

    Sunitinib

    go.drugbank.com/drugs/DB01268
    ApprovedInvestigational

    On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). … Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R).

  9. Drug

    Probenecid

    go.drugbank.com/drugs/DB01032
    ApprovedInvestigational

    The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubu...

  10. Drug

    Magnesium oxide

    go.drugbank.com/drugs/DB01377
    ApprovedInvestigational

    Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses.